• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Lab-Created Sugar-Coated Particles Block COVID-19 Infection—A Promising New Treatment Ahead

Bioengineer by Bioengineer
August 11, 2025
in Chemistry
Reading Time: 3 mins read
0
blank
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

blank

Groundbreaking research emerging from Swansea University reveals a revolutionary synthetic glycosystem capable of blocking SARS-CoV-2—the virus responsible for Covid-19—from infecting human cells with nearly 99% efficiency. This innovative development centers around a sugar-coated polymer nanoparticle meticulously engineered to imitate the natural sugar structures found on the surfaces of human cells. By mimicking these biological signatures, the glycosystem acts as a decoy, intercepting and neutralizing the virus before it can initiate infection.

The core of this discovery lies in the rational design of the synthetic molecule, which replicates polysialosides—polymers composed of repeating units of sialic acid, a sugar that many viruses exploit to attach to host cells. Through molecular mimicry, the nanoparticle binds selectively to the spike protein of SARS-CoV-2, outcompeting native sugars on cell membranes and effectively blocking viral entry. This mechanism operates independently of the immune system’s typical response, marking a departure from vaccines and traditional antiviral therapies.

Employing cutting-edge experimental methodologies, the research team quantified the interaction strength between the glycosystem and the viral spike protein. Remarkably, this synthetic polysialoside binds with an affinity approximately 500 times greater than chemically similar compounds lacking the precise sugar architecture, such as sulphated analogs. This heightened binding affinity underscores the critical importance of the sugar moieties’ spatial arrangement and conformation in achieving potent antiviral activity.

.adsslot_Xp24QtiB7y{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_Xp24QtiB7y{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_Xp24QtiB7y{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

The efficacy of this glycosystem is not limited to a single strain of the virus. Laboratory studies demonstrated robust inhibition against both the original SARS-CoV-2 isolate and the D614G variant, widely recognized for its increased transmissibility. Consequentially, the synthetic molecule exhibits broad-spectrum potential, positioning it as a versatile tool for combating existing and emergent viral strains.

In vitro experiments utilizing human lung cell cultures revealed a dramatic 98.6% reduction in viral infection when the glycosystem was applied. Such near-complete suppression at remarkably low dosages suggests a highly efficient mode of action with minimal cytotoxicity. This discovery could profoundly transform strategies for prophylaxis and treatment, particularly for vulnerable populations with diminished vaccine responsiveness.

Unlike conventional vaccines that stimulate adaptive immunity through antigen presentation, this synthetic glycosystem functions as a physical barrier, sequestering the virus extracellularly. By precluding the virus’s initial attachment phase, the nanoparticle prevents subsequent cellular entry and replication, fundamentally blocking the infectious cycle at its earliest stage.

The research consortium behind this breakthrough represents an international collaboration involving Swansea University, Freie Universität Berlin, and Charité – Universitätsmedizin Berlin. The interdisciplinary nature of the project—integrating chemistry, virology, and materials science—was pivotal in advancing the design, synthesis, and functional validation of the glycosystem, culminating in this unprecedented antiviral agent.

Future work aims to extend biological validation, including more comprehensive testing in biosafety level 3 laboratories to evaluate efficacy across diverse SARS-CoV-2 variants and related coronaviruses. Scaling from the molecular to the clinical realm will necessitate rigorous assessment of pharmacodynamics, bioavailability, and safety profiles to propel the glycosystem towards therapeutic application.

Potential real-world implementations envisioned include antiviral nasal sprays, topical surface disinfectants, and adjunctive treatment modalities designed to shield those at heightened risk, such as immunocompromised individuals or the elderly. These applications could provide rapid, non-immunogenic protection, complementing vaccination programs and enhancing public health defenses against future viral outbreaks.

This discovery not only expands the arsenal against Covid-19 but also exemplifies the transformative potential of nanotechnology and glycobiology in infectious disease control. By exploiting virus-host interaction pathways at a molecular level, researchers have carved a new paradigm for antiviral therapeutics centered on biomimicry and molecular precision.

The published study, titled “Polysialosides Outperform Sulfated Analogs for Binding with SARS-CoV-2,” appeared in the journal Small and outlines the comprehensive biochemical and virological data supporting the glycosystem’s efficacy. The authors confirm no conflicts of interest, underscoring the scientific integrity and collaborative transparency of the initiative.

As global efforts continue to confront evolving viral threats, this synthetic glycosystem heralds a promising frontier—a molecular shield that may soon fortify humanity’s defense strategies, transforming the landscape of viral infection prevention and paving the way for next-generation antiviral materials.

Subject of Research: Human tissue samples

Article Title: Polysialosides Outperform Sulfated Analogs for Binding with SARS-CoV-2

News Publication Date: 16-Jul-2025

Web References:
https://onlinelibrary.wiley.com/doi/10.1002/smll.202500719
https://www.swansea.ac.uk/staff/sumati.bhatia/
https://www.fu-berlin.de/
https://virologie-ccm.charite.de/en/

Keywords

COVID 19, Long Covid, Viral infections, COVID 19 vaccines, Disease outbreaks, Chemistry, Nanomaterials, Viruses, Coronavirus, SARS CoV 2, SARS CoV

Tags: alternative to traditional vaccinesengineered polymer nanoparticlesglycosystem binding affinityinnovative COVID-19 therapieslab-created treatment for COVID-19molecular mimicry in antiviral therapiespolysialosides in virus interceptionSARS-CoV-2 infection preventionsugar-coated nanoparticles for virus blockingSwansea University groundbreaking researchsynthetic antiviral strategiessynthetic glycosystem research

Share14Tweet9Share3ShareShareShare2

Related Posts

blank

SwRI Leads IMAP Payload Development for Upcoming Mission to Map Heliosphere Boundary

September 22, 2025
blank

Radical C–C Coupling Boosts CO₂ Electroreduction

September 22, 2025

Inside the Chemistry: Exploring the Process of Ammonia Synthesis

September 22, 2025

Deformable Particles Navigate and Settle in Microfluidic Channels

September 22, 2025

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    69 shares
    Share 28 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    50 shares
    Share 20 Tweet 13
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dual-Camera System Enhances Lower-Limb Kinematics in Osteoarthritis

Severe Obesity Linked to Lower Rates of Recommended Cancer Screenings

SwRI Leads IMAP Payload Development for Upcoming Mission to Map Heliosphere Boundary

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.